Publication date (Electronic, pub): 29 April 2023 Publication date (Electronic, collection): April 2023 Journal: Cureus Publisher: Cureus Keywords: hypertriglyceridemia-induced acute pancreatitis, hypertriglyceridemia, pembrolizumab, cancer immunotherapy, acute pancreatitis ...
主要研究目的: 比较在健康男性受试者中单次静脉注射BAT3306注射液或KEYTRUDA®(欧洲产品)后临床药代动力学的相似性。 次要研究目的: 评价BAT3306 注射液与KEYTRUDA®(欧洲产品)在健康男性受试者的临床安全性、耐受性及免疫原性 开始日期2023-10-31
I do want to take a moment, you and [David M.] O’Malley, [MD,] had a great publication in The Oncologist that talks about the regimen and how to manage treatment-related adverse effects. In that publication there is a figure that beautifully illustrates when might I expect to see thes...
Members who have experienced disease progression while on programmed death receptor-1 (PD-1) or PD-L1 inhibitor therapy (other than when used as second-line or subsequent therapy for metastatic or unresectable melanoma in combination with ipilimumab following progression on single agent anti-PD-1 im...
Immune checkpoint inhibitors (ICIs) show limited clinical activity in patients with advanced soft-tissue sarcomas (STSs). Retrospective analysis suggests that intratumoral tertiary lymphoid structures (TLSs) are associated with improved outcome in these patients. PEMBROSARC is a multicohort phase 2 study...
Today, new phase 2 safety and efficacy data was presented at AACR 2023 on mRNA-4157 (V940; Merck and Moderna), a personalized cancer vaccine combined with pembrolizumab (Merck), an anti-PD-1 therapy, as adjuvant treatment for high-risk melanoma.1 The presen...
WJ Jeon,J Nguyen,Castillo, Dani RanPark, KiwonBrothers, JoelNguyen, AnthonyMirshahidi, Hamid - 《Journal of Oncology Pharmacy Practice Official Publication of the International Society of Oncology Pharmacy Practitioners》 被引量: 0发表: 2023年 Third-line pembrolizumab-induced immune-related interstitial...
Consent for publication Not applicable. Competing interests TT has received honorarium from Merck Sharp & Dohme, Chugai, and AstraZeneca. OK and JS have nothing to disclose. MA reports honoraria from Roche, Pfizer, Amgen, and Merck & Co., Inc. MLQ reports travel expenses from Merck Sharp &...
- 《Journal of Thoracic Oncology Official Publication of the International Association for the Study of Lung Cancer》 被引量: 12发表: 2016年 Efficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenoca... ...
The sponsor and authors contributed to data collection and writing of the manuscript and approved the decision to submit the final manuscript for publication. The data from the trial were held and statistically analyzed by Precision for Medicine and checked by authors. Prior work supporting this ...